Please assess the completion status of the following clinical trial:

Trial Title: VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed diagnosis of recurrent NMIBC (urothelial carcinoma) including repeat TURB confirming tumor-free state of the bladder (confirmed by TURB and biopsy) For patients with pure CIS of the bladder no repeat TURB is necessary.~* Negative cytology before start of treatment, except for patients with concomitant CIS.~* Planned treatment starts 2-5 weeks after last TURB~* Pathological grading includes reporting according to WHO 1973 and 2004.~* One previous cycle of intravesical BCG (induction phase with at least 5 instillations ± maintenance) not more than 5 years ago for NMIBC.~* Patients have recurrent high-risk NMIBC for progression.~Exclusion Criteria:~* Current or previous ≥ T2 urothelial carcinoma (UC) of the urinary bladder~* Bladder surgery or traumatic catheterization or TURB within 2 weeks prior to the expected start of trial treatment~* Stress urinary incontinence \>I°, severe urge or urge urinary incontinence preventing the patient to keep the IMP in the bladder for at least 1 hour. Residual urinary bladder volume after micturition is \> 150 ml.~* Active concomitant malignant conditions except low risk prostate cancer qualifying for active surveillance according to PRIAS criteria (http://www.prostatecancer-riskcalculator.com/active-surveillance-and-prias-study), basal cell skin carcinoma and cervical carcinoma in situ. History of malignancy in the last 3 years except previous NMIBC.~* Primary or secondary immunodeficiencies~* Positive HIV test~* Chronic administration (defined as more than 14 consecutive days) of immunosuppressive drugs or other immune modifying drugs within three months before instillation~* Uncontrollable urinary tract infection, macroscopic haematuria, suspicion of bladder perforation, urethral strictures (if interfering with trial procedures)~* Current and past pelvic radiation and brachytherapy~* Active tuberculosis or other ongoing mycobacterial infection.~* History of anaphylaxis or severe allergic reactions, known allergies to any component of the investigational product, BCG intolerance~* Local and severe allergy (e.g. ulceration, systemic reactions) to PPD test~* Acute fever or fever (\>38.5˚C) in the last 7 days before registration~* Simultaneous administration of antituberculous agents and antibiotics that cannot be stopped until registration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- VPM1002BC Induction (Type: EXPERIMENTAL): Phase 1:~Induction: 6 intravesical instillations of VPM1002BC in 6-12 weeks (dose de-escalation in cohorts of 3-6 patients)~Phase 2:~Induction: VPM1002BC at RP2D established in phase I, 6 intravesical instillations in 6-12 weeks (n=39 including patients treated at RPD2 in phase I)~Maintenance: 3 instillations of VPM1002BC at months 3, 6 and 12

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete